T 1491/14 (Vortioxetine/LUNDBECK) of 30.07.2019

European Case Law Identifier: ECLI:EP:BA:2019:T149114.20190730
Date of decision: 30 July 2019
Case number: T 1491/14
Petition for review of: -
Application number: 08850935.1
IPC class: A61P 25/00 A61K 31/495
Language of proceedings: English
Distribution: No distribution (D)
Download: Decision in English
OJ versions: No OJ links found
Other decisions for this case: -
Abstracts for this decision: -
Application title: THERAPEUTIC USES OF COMPOUNDS HAVING COMBINED SERT, 5-HT3 AND 5-HT1A ACTIVITY
Applicant name: H. Lundbeck A/S
Takeda Pharmaceuticals U.S.A., Inc.
Opponent name: SANDOZ AG
Board: 3.3.01
Headnote: -
Relevant legal provisions: European Patent Convention Art 100(a)European Patent Convention Art 54 European Patent Convention Art 56 European Patent Convention Art 83
Keywords: Novelty - main request (yes)
Novelty - new group of patients
Inventive step - auxiliary request 1 (yes)
Inventive step - no one-way-street situation
Sufficiency of disclosure - auxiliary request 1 (yes)
Catchword: -
Cited cases: G 0003/14 T 0619/02
Citing cases: T 2344/19 T 0910/21 T 1390/22 T 1898/23 T 0136/24

Order

For these reasons it is decided that:

The appeals are dismissed.